Using registries to identify adverse events in rheumatic diseases

Pediatrics

Volumn 132, Issue 5, 2013, Pages

  Lionetti, Geraldina ^a   Kimura, Yukiko ^b   Schanberg, Laura E ^c   Beukelman, Timothy ^d   Wallace, Carol A ^e   Ilowite, Norman T ^f   Winsor, Jane ^g   Fox, Kathleen ^g   Natter, Marc ^h   Sundy, John S ^g   Brodsky, Eric ⁱ   Curtis, Jeffrey R ^d   Gaizo, Vincent Del ^j   Iyasu, Solomon ⁱ   Jahreis, Angelika ^k   Meeker O'connell, Ann ⁱ   Mittleman, Barbara B ^l   Murphy, Bernard M ^m   Peterson, Eric D ^g   Raymond, Sandra C ⁿ   Setoguchi, Soko ^g   Siegel, Jeffrey N ^k   Sobel, Rachel E ^o   Solomon, Daniel ^p   Southwood, Taunton R ^q   Vesely, Richard ^r   White, Patience H ^m   Wulffraat, Nico M ^s   Sandborg, Christy I ^a   more..

^a STANFORD UNIVERSITY   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

^e SEATTLE CHILDREN S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j Friends of Childhood Arthritis and Rheumatology Research Alliance   (United States)

^k GENENTECH INC   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m ARTHRITIS FOUNDATION   (United States)

ⁿ Lupus Foundation of America Inc   (United States)

^o PFIZER INC   (United States)

^p BRIGHAM AND WOMEN S HOSPITAL   (United States)

^q UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^r EUROPEAN MEDICINES AGENCY   (United Kingdom)

^s UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Biologic products; Immunomodulatory therapy; Juvenile rheumatic disease; Medication safety

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; IMMUNOMODULATING AGENT; METHOTREXATE;

ACCESS TO INFORMATION; ARTICLE; CHILD CARE; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; DISEASE REGISTRY; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; INFECTION; INFORMATION PROCESSING; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; PATENT; PATIENT ADVOCACY; PATIENT INFORMATION; POLYPHARMACY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNITED STATES; REGISTER; RHEUMATIC DISEASES; STANDARDS;

BIOLOGICAL PRODUCTS; HUMANS; REGISTRIES; RHEUMATIC DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84887058773     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-0755     Document Type: Article

References (34)

1. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: Treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009;11(1):216.
2. Lovell DJ, Giannini EH, Reiff A, et al; Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342(11):763-769. (Pubitemid 30151920)
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-259. (Pubitemid 29063266)
4. Rodriguez W, Selen A, Avant D, et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics. 2008;121(3):530-539.
5. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62(8):2517-2524.
6. Beukelman T, Haynes K, Curtis JR, et al; Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263-1271.
7. Harrison M, Nordstrom B, Gu Y, Mercaldi C, Aquino P, Mines D. Risk of malignancy in biologics-naive juvenile arthritis patients [abstract]. Ann Rheum Dis. 2010;69(suppl 3):631.
8. Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64(9):1357-1364.
9. Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study. Arthritis Rheum. 2010;62(12):3776-3782.
10. Bernatsky S, Rosenberg AM, Oen KG, et al. Malignancies in juvenile idiopathic arthritis: A preliminary report. J Rheumatol. 2011;38(4):760-763.
11. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of newonset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr. 2006;149(6):833-836. (Pubitemid 44816346)
12. van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38(7):1441-1446.
13. Winthrop KL, Chen L, Fraunfelder FW, et al. Initiation of anti-TNF therapy and the risk of optic neuritis; from the Safety Assessment of Biologic ThERapy (SABER) Study. Am J Ophthalmol. 2012;155(1):183-189.
14. Kimura Y, Weiss JE, Haroldson K, Lee T, Punaro M, Oliveira S, et al; CARRAnet Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(5):745-752.
15. Safe and Effective Medicines for Children. Pediatric studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. In: Marilyn J, ed. Institute of Medicine. Washington, DC: Field TFB; 2012.
16. Fact Sheet: Pediatric provisions in the Food and Drug Administration Safety and Innovation Act (FDASIA). Available at: www.fda.gov/ RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/ SignificantAmendmentstotheFDCAct/FDASIA/ucm311038.htm.
17. Mathis LL, Iyasu S. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned. Clin Pharmacol Ther. 2007;82(2):133-134. (Pubitemid 47075349)
18. Smith PB, Benjamin DK Jr, Murphy MD, et al. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics. 2008;122(3). Available at: www.pediatrics.org/cgi/content/full/122/3/e628.
19. Field MJ, Ellinger LK, Boat TF. IOM Review of FDA -approved biologics labeled or studied for pediatric use. Pediatrics. 2013;131(2):328-335.
20. Section 505B of the Federal Food, Drug, and Cosmetic Act [21U.S.C. 355c] 2002: 124. Available at: www.epw.senate.gov/FDA-001.pdf.
21. Lovell DJ, Ruperto N, Goodman S, et al; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810-820.
22. Ruperto N, Lovell DJ, Cuttica R, et al; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096-3106. (Pubitemid 47502757)
23. Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383- 391.
24. Beukelman T, Xie F, Chen L, et al; SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773-2780.
25. Giannini EH, Ilowite NT, Lovell DJ, et al; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794-2804.
26. Childhood Arthritis and Rheumatology Research Alliance (CARRA). Available at: www.carragroup.org. Accessed June 2013.
27. Duke Clinical Research Institute. Available at: https://dcri.org/Accessed June 2013.
28. Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: Time for a consolidated patient registry. Arthritis Care Res (Hoboken). 2010;62(6):800-804.
29. Natter MD, Quan J, Ortiz DM, et al. An i2b2- based, generalizable, open source, selfscaling chronic disease registry. J Am Med Inform Assoc. 2013;20(1):172-179.
30. Weber GM, Murphy SN, McMurry AJ, et al. The Shared Health Research Information Network (SHRINE): A prototype federated query tool for clinical data repositories. J Am Med Inform Assoc. 2009;16(5):624-630.
31. Amin W, Singh H, Pople AK, et al. A decade of experience in the development and implementation of tissue banking informatics tools for intra and inter-institutional translational research. J Pathol Inform. 2010;1(Aug 10):ii.
32. Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA; CARRA Registry Investigators. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2012;39(12):2341-2351.
33. Beukelman T, Ringold S, Davis TE, et al; CARRA Registry Investigators. Diseasemodifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867-1874.
34. Ringold S, Beukelman T, Nigrovic PA, Kimura Y; CARRA Registry Site Principal Investigators. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013;40(6):936-942.